Science
Mechanism of Action
This molecule acts as a cell-permeable shield that targets the mitochondria to scavenge ROS and RNS. It specifically inhibits the release of High-mobility group box 1 (HMGB1)—a potent inflammatory mediator—and prevents caspase-independent necrotic cell death by maintaining mitochondrial membrane integrity and downregulating pro-inflammatory cytokines.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 In vivo murine models demonstrated that 0.3 mg/kg significantly reduced histologic damage scores in skin and liver tissues by inhibiting HMGB1 expression.
- 02 Human clinical trials using doses up to 200 mg (IV) and 30 mg (multiple doses) confirmed the compound is well-tolerated with no dose-limiting toxicities.
- 03 In vitro studies on H9C2 cells at 400 µM showed a significant reduction in mitochondrial ROS and RNS accumulation after induced oxidative stress.
Transparency
Dusting Analysis
As a specialized medical-grade compound primarily seen in clinical research (NecroX/MIT-001), it is not a common 'marketing' ingredient. Its inclusion usually indicates a highly technical formulation rather than label dusting.
The Formula
Formulation
Stability
Currently utilized in both intravenous and subcutaneous medical preparations; stability in complex cosmetic emulsions is still being established.
Synergies
- Mitochondrial-targeted nutrients
- Anti-inflammatory lipids
- Cell-signaling peptides
Safety
Safety Profile
While not yet a standard INCI-listed cosmetic ingredient, human clinical trials for its therapeutic variants show excellent systemic tolerance, with only mild local reactions reported at injection sites.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A high-potential, medical-grade antioxidant that offers unique mitochondrial protection and anti-inflammatory benefits beyond standard vitamins.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources